Keros Therapeutics, Inc.
KROS
$10.10
-$0.56-5.25%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -28.71M | -23.71M | -23.46M | -7.28M | -30.70M |
| Total Depreciation and Amortization | 402.00K | 403.00K | 400.00K | 395.00K | 370.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.03M | 6.84M | 7.93M | 4.60M | 9.12M |
| Change in Net Operating Assets | 1.86M | 12.94M | -12.16M | 5.54M | -8.42M |
| Cash from Operations | -20.42M | -3.53M | -27.29M | 3.25M | -29.62M |
| Capital Expenditure | -155.00K | -73.00K | -134.00K | -132.00K | -720.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -155.00K | -73.00K | -134.00K | -132.00K | -720.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23.00K | 7.00K | 127.00K | 140.00K | 17.00K |
| Repurchase of Common Stock | -3.34M | -2.32M | -378.90M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 139.00K | -- | -- |
| Cash from Financing | -3.32M | -2.32M | -378.63M | 140.00K | 17.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.89M | -5.92M | -406.06M | 3.26M | -30.33M |